|1.||Gale, Richard P: 2 articles (09/2015 - 01/2015)|
|2.||Virgili, Gianni: 2 articles (01/2015 - 05/2014)|
|3.||Kaasalainen, Sharon: 2 articles (12/2014 - 08/2010)|
|4.||Ueta, Takashi: 2 articles (11/2014 - 04/2014)|
|5.||Bandello, Francesco: 2 articles (11/2014 - 01/2013)|
|6.||Iacono, Pierluigi: 2 articles (11/2014 - 01/2013)|
|7.||Kampik, Anselm: 2 articles (10/2014 - 04/2014)|
|8.||Wolf, Armin: 2 articles (10/2014 - 04/2014)|
|9.||Simader, Christian: 2 articles (08/2014 - 10/2013)|
|10.||Schmidt-Erfurth, Ursula: 2 articles (08/2014 - 09/2012)|
|1.||Macular Degeneration (Age-Related Maculopathy)
04/01/2014 - "To assess healthcare processes during treatment of neovascular age-related macular degeneration (AMD) in patients under real-life conditions and evaluate efficacy of monthly visual acuity (VA) assessment in a pro re nata treatment regime. "
01/01/2015 - "To investigate whether treatment as required 'pro re nata' (PRN) versus regular monthly treatment regimens lead to differences in outcomes in neovascular age-related macular degeneration (nAMD). "
12/01/2012 - "To investigate the safety and efficacy of a combined fixed-interval and pro re nata regimen of ranibizumab (FUSION regimen) for treatment of exudative age-related macular degeneration in patients with good visual acuity at baseline. "
05/01/2014 - "To evaluate the efficacy of intravitreal ranibizumab with a "pro re nata" regimen in the treatment of nonsubfoveal neovascular membranes secondary to age-related macular degeneration. "
05/01/2011 - "Long-term efficacy and safety of ranibizumab administered pro re nata in Japanese patients with neovascular age-related macular degeneration in the EXTEND-I study."
12/01/2013 - "To determine the efficacy of 1 intravitreal bevacizumab injection followed by pro re nata (1 + PRN) injection in cases of subfoveal myopic choroidal neovascularization (CNV) and to identify CNV-recurrence-related prognostic factors. "
01/01/2015 - "The current study investigated the impact of treatment with ranibizumab as needed (pro re nata [PRN]) on individuals with myopic choroidal neovascularization (mCNV) in the REPAIR study, using patient-reported outcome measures (PROMs) for treatment satisfaction and well-being. "
01/01/2015 - "Choroidal neovascularization treated with induction/pro re nata intravitreal ranibizumab for 1 year essentially remained static. "
01/01/2013 - "The treatment of pigment epithelial detachment associated with occult subfoveal choroidal neovascularization with intravitreal ranibizumab injection after a 3-monthly loading phase and pro re nata strategy can lead to partial results over a 24-month follow-up. "
05/01/2011 - "To evaluate the long-term efficacy and safety of ranibizumab administered pro re nata (PRN) in Japanese patients with choroidal neovascularization secondary to age-related macular degeneration during the extension phase of the EXTEND-I study. "
12/01/2014 - "In a previous study, implementation of a pain assessment protocol resulted in changes in administration of pro re nata (PRN) medications and positive outcomes. "
07/01/2014 - "The participants consisted of 52 long-stay NH residents capable of self-consent with at least one order for pain medication (opioid or non-narcotic) either pro re nata, scheduled or both. "
07/01/2013 - "A pattern of care emerged of giving pain medications regularly even if they were prescribed pro re nata. "
02/01/2011 - "Boluses commenced from the onset of pain and continued for >48 h as required (pro re nata, PRN) up to every hour for a numerical rating pain score (NRPS, 0-10) >2. Group 2 ml h⁻¹ received mandatory 6 hourly boluses irrespective of the NRPS. "
08/01/2010 - "Eliciting reports of pain, offering pro re nata pain relief regularly, utilizing pain assessment tools in patients with cognitive impairment, redesigning documentation tools and processes, making nonpharmacological alternatives accessible, and helping patients and families manage side effects would target the 12 barriers having the biggest impact."
01/01/2016 - "The delirium management regimen included timely administration of pro re nata medication. "
09/01/2012 - "This study examined the relationship between nurses' pro re nata administration of midazolam hydrochloride to cardiac surgery patients and the development of post-operative delirium. "
12/01/2015 - "Although 62% of patients were on around-the-clock (ATC) neuroleptics to treat delirium, about two thirds of these were requiring rescue doses (PRN [pro re nata]) as well. "
09/01/2012 - "Numerous risk factors for delirium are uncontrollable; however, nurses' pro re nata drug administration of sedatives may be a controllable risk factor. "
02/01/2012 - "This study identified how unlicensed staff members decide to administer medications prescribed pro re nata (PRN) to residents of assisted living (AL) settings designated for persons with dementia. "
05/01/2015 - "The use of "pro re nata" (PRN) medication in patients with behavioral and psychological symptoms of dementia (BPSD) is common but may be a source of inappropriate medication administration. "
02/01/2012 - ""Learning about your residents": how assisted living residence medication aides decide to administer pro re nata medications to persons with dementia."
|5.||Analgesics (Analgesic Drugs)
|6.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|8.||Morphine (MS Contin)
|1.||Photochemotherapy (Photodynamic Therapy)